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Dengue, caused by four dengue virus serotypes
(DENV-1 to DENV-4), is a highly prevalent mos-
quito-borne viral disease in humans. Yet, selection
pressures driving DENV microevolution within
human hosts (intrahost) remain unknown. We em-
ployed a whole-genome segmented amplification
approach coupled with deep sequencing to profile
DENV-3 intrahost diversity in peripheral bloodmono-
nuclear cell (PBMC) and plasma samples from 77
dengue patients. DENV-3 intrahost diversity appears
to be driven by immune pressures as well as replica-
tive success in PBMCs and potentially other replica-
tion sites. Hotspots for intrahost variation were
detected in 59%–78% of patients in the viral Enve-
lope and pre-Membrane/Membrane proteins, which
together form the virion surface. Dominant variants
at the hotspots arose via convergent microevolution,
appear to be immune-escape variants, and were
evolutionarily constrained at the macro level due to
viral replication defects. Dengue is thus an example
of an acute infection in which selection pressures
within infected individuals drive rapid intrahost virus
microevolution.
INTRODUCTION
Dengue virus (DENV) is a mosquito-borne Flaviviruswith a single-
strandedRNAgenome that causesanestimated390million infec-
tions and up to 96 million dengue cases worldwide every year
(Bhatt et al., 2013). There are four closely related serotypes of
DENV (DENV-1 to DENV-4), each of which encodes three struc-
tural proteins (Capsid [C], pre-Membrane/Membrane [prM/M],
and Envelope [E]) and seven non-structural (NS) proteins (NS1,
NS2A, NS2B, NS3, NS4A, NS4B, NS5). Infections with DENV
can result in a spectrum of clinical manifestations, ranging from
asymptomatic infection to the debilitating acute febrile illness,400 Cell Host & Microbe 22, 400–410, September 13, 2017 ª 2017 Edengue fever (DF), to the life-threatening dengue hemorrhagic
fever/dengue shock syndrome (DHF/DSS) (WHO, 1997). Major
determinants of dengue pathogenesis include virulence of the in-
fecting DENV strain, host genetic factors, and pre-existing host
immune responses from prior infection(s) with a different DENV
serotype (Halstead and Yamarat, 1965; Messer et al., 2003;
Nguyen et al., 2008; OhAinle et al., 2011; Rico-Hesse et al.,
1997). In sequential infections, disease severity appears to be
determined by a complex interplay of protective and enhancing
components from pre-existing immunity to viral antigens (Hal-
stead, 2009; Peiris and Porterfield, 1979; Rothman and Ennis,
1999). Such intricacies of the human immune response to DENV
infection have made it difficult not only to identify the precise
mechanisms that trigger progression to severe disease but also
to engineer vaccines and therapeutics for combating the disease.
Replication of DENV within each host produces a population
of genetically related but distinct genomes (referred to as intra-
host diversity) due to the error-prone nature of the viral replicase,
the RNA-dependent RNA polymerase (RdRP) (Domingo and
Holland, 1997). These intrahost variants are thought to serve
as templates on which evolutionary mechanisms act to shape
variation at the consensus level between hosts (i.e., interhost
diversity), leading to the emergence of genetically distinct strains
and genotypes of DENV. Genetic variations in intrahost popula-
tions have been proposed to influence disease outcome and
pathogenesis in chronic human infections with RNA viruses
such as HIV and hepatitis C virus (HCV) (Farci et al., 2002;
Joos et al., 2005; Lee et al., 2008; Moreau et al., 2008; Sullivan
et al., 2007), which provide considerable time frames (months
to years) for discernible virus evolution in response to intrahost
selection pressures. Similar observations have also been re-
ported in chronic infections with influenza virus and norovirus,
viruses that are usually associated with acute infections (Bull
et al., 2012; Debbink et al., 2014; Rogers et al., 2015; Valkenburg
et al., 2013). These studies have characterized the emergence of
individual variants associated with immune evasion or drug
resistance. Unlike chronic infections, only a handful of studies
have reported on the evolutionary mechanisms and viral ge-
netics driving virus evolution in acute human infections such as
Ebola (Gire et al., 2014; Ni et al., 2016), chikungunya (Stapleford
et al., 2016), influenza A (Sobel Leonard et al., 2016), Middle Eastlsevier Inc.
Table 1. Summary of Samples Used in This Study
Sample
Typea
Year of
Collection
Disease
Severity
Immune
Status
No. of
Samplesb
No. of Paired
Samplesb
PBMCs 2009–2010 DF primary 32 11
secondary 23 9
DHF/DSS primary 5 0
secondary 8 2
Plasma 2009–2010 DF primary 16 11
secondary 13 9
DHF/DSS primary 0 0
secondary 2 2
aPBMC and plasma samples (including 53 primary and 46 secondary
samples) were obtained from individuals aged 6 months to 14 years
who were enrolled in the hospital-based pediatric dengue study and
tested positive for DENV-3.
bOnly nucleotide loci with coverage ofR1,000 reads and locus-specific
Sanger quality scores of R30 were considered for calculating genome
coverage. Samples withR50% genome coverage are reported.respiratory syndrome (Park et al., 2016), and dengue (Parames-
waran et al., 2012; Rodriguez-Roche et al., 2016; Sessions et al.,
2015; Sim et al., 2015; Thai et al., 2012), where virus evolution is
severely constrained by time (days to weeks). Consequently,
limited information exists about the fitness and pathogenesis
profiles of individual intrahost DENV variants that emerge in
acute human infections. Information on intrahost viral diversity
can provide new perspectives in assessing infection outcome,
disease pathogenesis, and vaccine or therapeutic efficacy in
individuals with dengue or other closely related viral infections
such as Zika.
In this study, we employ a whole-genome segmented amplifi-
cation approach coupled with high-throughput sequencing to
profile intrahost viral diversity across the entire coding region
of the DENV-3 genome with considerable depth of coverage.
Using snapshots of DENV-3 intrahost diversity in 31 plasma
and 68 peripheral blood mononuclear cell (PBMC) samples
from 77 individuals (including 22 with paired plasma and
PBMC samples) enrolled in a prospective pediatric hospital-
based study in Nicaragua, we demonstrate that DENV-3 diversi-
fication in human acute dengue (microevolution) is shaped by
convergent selection pressures, including pre-existing immu-
nity, and possibly by replication in sites other than PBMCs, while
it is constrained by severe defects in replicative ability.
RESULTS AND DISCUSSION
Samples and Methods
All PBMC and plasma samples used in this study were collected
on the first day of presentation from individuals aged 6months to
14 years with primary (1; 53 samples) or secondary (2; 46
samples) acute, symptomatic DENV-3 infection during the
2009–2010 epidemic season in Managua, Nicaragua (Tables 1
and S1) (Narvaez et al., 2011). The majority of PBMC (82%)
and plasma (91%) samples were from individuals who presented
with DF. The rest of the PBMC (18%) and plasma (9%) samples
were from individuals who presented with DHF/DSS. Supporting
clinical information is provided in Table S1.The DENV-3 genome was amplified via reverse transcription
and PCR using sequence-specific primer pairs to generate
12 overlapping amplicons per sample (Figure S1A). Multiplexed
libraries for high-throughput sequencing were constructed from
pooled amplicon mixes and sequenced on an Illumina HiSeq
2000 platform to yield 150-nucleotide (nt) paired-end reads in
forward (read 1) and reverse (read 2) orientations. Reference
genomes were reconstructed for each sample using Bowtie2
(Langmead and Salzberg, 2012) and SAMtools (Li et al., 2009),
and in-house python scripts were used to calculate variation at
the nucleotide, codon, and amino acid levels for each locus in
the DENV-3 coding region (see STAR Methods). After filtering
for coverage (R1,000 reads) and Sanger quality scores (R30),
median coverage per codon locus was 22,975 and 20,024 for
read 1 and read 2 datasets, respectively. Only samples with
R50% coverage of the DENV-3 genome were retained for
downstream analyses; 68 PBMC and 31 plasma samples from
77 individuals, including paired PBMC-plasma datasets from
22 individuals, passed the threshold for genome coverage. Cod-
ing-region coverage in these samples varied between 50.7%
and 99.9% (median of 98.9%) for both read 1 and read 2 data-
sets combined (Table S1).
Percent variant diversity at nucleotide, codon, and amino
acid loci was calculated as the percent of reads spanning each
coordinate that was different from consensus. Nucleotide- and
codon-level diversities provide aggregate measures of both
non-synonymous and synonymous mutations (i.e., mutations
that do and do not change amino acid encoding, respectively),
while amino acid diversity only captures non-synonymous
mutations. In our study, variant abundances of R1.0% were
reproducible across replicates (see STAR Methods) and were
considered variants of high confidence. Unless otherwise spec-
ified, we used high-confidence variants for investigating diversity
patterns. Samples from both sexes were included in all intrahost
diversity comparisons; no significant differences between sexes
were observed for any of the calculated DENV-3 intrahost diver-
sity metrics (data not shown).
Intrahost Immune Pressures Shape DENV-3 Diversity in
Acute Human Infections
We evaluated snapshots of intrahost diversity in samples from
distinct subsets of individuals with 1 (53 samples) or 2 (46 sam-
ples) dengue to assess the effects of immune-driven selection
pressures on intrahost DENV evolution. We compared the
percent loci per protein that are variant in any sample between
1 and 2 dengue and found significantly fewer unique variant
loci in 2 dengue cases, both in PBMC (Figure 1A; left panel,
p < 0.001) and plasma (Figure 1A; right panel, p < 0.01) samples.
These observations were not due to systematic disparities in the
yields of viral RNA, since measures of genome equivalents (GE)
per milliliter of extracted viral RNA were not significantly different
between 1 and 2 cases for both PBMC and plasma samples
(Figure 1B; left and right panels). Thus, DENV-3 appears to be
evolving at fewer distinct loci genome-wide in 2 dengue
comparedwith 1 dengue, suggesting that virus evolution is con-
strained by pre-existing immune pressures in 2 dengue. In addi-
tion, we examined the locations of unique variant loci on the
exposed and membrane-associated surfaces of the E protein,
which is a prominent target for antibody-mediated immunity inCell Host & Microbe 22, 400–410, September 13, 2017 401
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Figure 1. DENV-3 Intrahost Diversity Is Shaped by Selection Pressures
(A) Percent unique loci per protein with amino acid diversity, calculated as the percent of amino acids in a protein that showR1% variation, in PBMC (left panel)
and plasma (right panel) samples from 53 individuals with 1 and 46 individuals with 2 dengue. *p% 0.01, **p% 0.001 (Wilcoxon signed-rank test). Each line
represents one protein.
(B) Comparisons of genome equivalents per milliliter (GE/mL) of extracted RNA in 53 1 and 46 2 cases from PBMC (left panel) and plasma (right panel) samples,
median ± SD, boxes represent 25th and 75th percentiles and whiskers are 10th and 90th percentiles. n.s., non-significant (Wilcoxon test for unpaired samples).
(C) All loci withR1% variation at the amino acid level, superimposed on the exposed surface (left panel) or the membrane-associated surface (right panel) of the
DENV-3 E protein homodimer (PDB: 1UZG). Amino acids are colored according to whether they exhibit diversity in PBMC samples only (PBMCs, red), in plasma
samples only (Plasma, blue), or in both PBMCs and plasma (Both, green). Data are shown separately for 53 1 (top panel) and 46 2 (bottom panel) dengue cases.
EDIa/b, EDIIa/b, EDIIIa/b represent E domains I, II, and III from monomer chains a and b, respectively.
(D) Percent amino acid variants for loci that exhibit diversity in PBMCs only (PBMCs), compared with loci that exhibit diversity in both PBMCs and plasma (Both),
median ± SD, boxes represent 25th and 75th percentiles and whiskers are 10th and 90th percentiles. In the left panel, the y axis represents the percent abundance
of non-synonymous variants in PBMCs. In the right panel, the y axis represents the percent abundance of synonymous variants in PBMCs. **p % 0.0001
(Wilcoxon test), n = 22 paired PBMC and plasma samples.
(E) Protein-specific comparisons of percent amino acid variants in 22 paired PBMC and plasma samples, colored by whether individual loci displayR1% amino
acid diversity in PBMC samples only (yellow), in plasma samples only (red), or in both PBMC and plasma samples (green). Data are shown for the two proteins
(legend continued on next page)
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human dengue. We detected fewer unique variant loci across all
samples in 2 dengue cases compared with 1 cases (Figure 1C;
top and bottom panels) on both the exposed and themembrane-
associated surfaces of E; much of this difference was contrib-
uted by PBMC-specific variant loci. Thus, consistent with
genome-wide differences between 1 and 2 dengue, the
breadth of the viral variant repertoire in E appears to be reduced
in 2 dengue compared with 1 dengue. Such global differences
in viral composition between naive individuals and individuals
with pre-existing immunity to DENV indicate that the extent of
diversity in the intrahost DENV-3 population is directed by the
immune repertoire during acute dengue in humans. Further
studies investigating particular epitopes will help resolve the
specificities of pre-existing immune pressures contributing to
differential rates of viral microevolution in 1 and 2 dengue.
Selection Pressures Shape DENV-3 Microevolution in
Plasma
We used patterns of DENV-3 intrahost diversity in paired PBMC
and plasma samples from a subset of 22 individuals to assess
the role of selection pressures mediated by human immune
pathways or virion intracellular replicative success in shaping
differences in DENV variants at the PBMC-plasma (i.e., intracel-
lular-extracellular) interface and to explore the relative contribu-
tions from PBMCs and other potential viral replication sites to
circulating virion populations in plasma.
We examined the percent abundance of non-synonymous
variants in PBMCs and plasma, binning loci by whether variants
were found at levels R1% in PBMCs only (PBMCs), or in both
PBMC and plasma samples (Both). The median percent abun-
dance of variant DENV-3 genomes that were found in PBMCs
only was significantly lower than the median percent abundance
of variant genomes found in both PBMCs and plasma, for both
non-synonymous and synonymous variants (Figure 1D, left and
right panels, p < 0.0001). Thus, variants that appear in both
PBMCs and plasma are more abundant than variants that are
restricted to PBMCs, suggesting that DENV variants found in
plasma have been selected based on their intracellular replica-
tive success in PBMCs.
We also found evidence for immune-driven selection pres-
sures shaping differences between plasma and PBMC DENV
populations. In particular, significantly higher abundances for
non-synonymous variants were observed in plasma compared
with PBMCs for the prM/M and NS3 proteins (Figure 1E,
p < 0.0001), which are major targets of the human B cell and
T cell immune responses, respectively (de Alwis et al., 2014; Dej-
nirattisai et al., 2010; Rivino et al., 2013; Simmons et al., 2005;
Weiskopf et al., 2013).
Furthermore, we observed many dissimilarities between
PBMCs and plasma DENV populations that could not be attrib-
uted to replication defects or immune pressure mechanisms. For
instance, minimal intersection was detected in the locations of
variant loci on the highly antigenic E protein (Figure 1C, green
loci), as well as in other proteins (Figures 1E and S2A), inferred(prM/M and NS3) that exhibit significant differences in% amino acid (AA) variants
an example) exhibit no significant differences in % AA variants between PBMCs
(F) Comparisons of genome equivalents per milliliter (GE/mL) of extracted RNA in
rank test for paired samples).from the presence of fewer green lines representing loci with
R1% amino acid variants in both PBMC and plasma samples,
compared with orange and red lines representing loci with
R1% amino acid variants in PBMC or plasma samples, respec-
tively. These findings were not due to differences in the depth of
sequencing coverage (data not shown), or in the number of viral
copies used as input for generating sequencing libraries (Fig-
ure S2B), because these parameters were comparable between
paired PBMC and plasma samples. These observations of large-
scale differences between plasma and PBMC DENV variant
populations, when taken together with prior knowledge from
human autopsy studies about the existence of significant
non-PBMC compartments for viral replication in phagocytes,
lymph node, spleen, alveolar macrophages in lung, and perivas-
cular cells in brain (Aye et al., 2014; Balsitis et al., 2009; Jessie
et al., 2004), suggest contribution to plasma DENV populations
from replication compartments other than PBMCs.
Hotspots for DENV-3 Intrahost Diversity in Acute Human
Dengue
We next sought to identify hotspots for intrahost viral diversity,
defined as loci with detectable intrahost diversity in multiple
hosts, in PBMC and plasma samples from individuals with
DENV-3 infection. Hotspots may arise de novo within each
host due to convergent selection pressures, or may be attributed
to the co-transmission of wild-type (WT) and variant viruses
within a host population. The probability of detecting diversity
hotspots due to selection pressures has been assumed to be
low in acute human dengue (Descloux et al., 2009; Lin et al.,
2004; Parameswaran et al., 2012; Thai et al., 2012; Wang
et al., 2002a, 2002b), primarily because of the time constraint
(8–14 days) on virus evolution within hosts.
We analyzed percent variant abundance together with percent
prevalence of variants at each codon locus (depicted by the
color and size of each data point) across the entire DENV-3 cod-
ing region and found that very few codon loci were hotspots for
intrahost diversity in PBMC and plasma samples (Figure 2A, top
and bottom panels, respectively). However, prominent hotspots
for diversity were identified in the majority (59%–78%) of sam-
ples at three codon coordinates: (1, 2) 214 and 215, correspond-
ing to amino acids 100 and 101 in the membrane portion of
prM/M (hereafter prM100 and prM101), and (3) 595, corresponding
to amino acid 315 in the highly conserved AB-loop region in
E Domain III (E315) (Figures 2A and 2B). To confirm the presence
of the more abundant E315 variant, we designed primers that
specifically targeted and amplified either WT or E315 DENV
RNA and validated the specificity of these primers using RNA
fromWT or E315 variant viruses (Figure S3A). We tested a subset
of seven serum samples used in this study and were able to
directly detect the E315 hotspot variant at various levels in all
seven clinical samples (Figure S3B).
The dominant variants at these hotspots were identical across
samples (Figure S2C) and exhibited altered amino acid
sequence compared with consensus: (1) glycine to serine atbetween PBMCs and plasma. All other proteins (including E, which is shown as
and plasma. **p% 0.0001, n.s., non-significant (Wilcoxon signed-rank test).
12 paired PBMC and plasma samples. n.s., non-significant (Wilcoxon signed-
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Figure 2. Hotspots for Intrahost Diversity in the DENV-3 Genome
(A) Percent intrahost codon diversity (y axis) across the coding region of DENV-3 (x axis) in 68 PBMC (top panel) and 31 plasma (bottom panel) samples; each data
point is colored according to the number of samples in whichR1% intrahost diversity is detected at that locus.
(B) Major variants at the hotspot loci in prM/M (top) and E (bottom). Red asterisk, furin cleavage site.
(C) Prevalence of major hotspot loci (i.e., loci withR1% variant abundance inR50% of samples) in 68 plasma (right panel) and 31 PBMC (left panel) samples in
both read orientations (read 1 in yellow and read 2 in red).
(D) Percent samples with diversity at each hotspot locus, shown for increasing cutoffs for percent intrahost codon diversity, in the 68 PBMC (left panel) and
31 plasma (right panel) datasets.
(E) Average percent intrahost (yellow) and percent interhost (red) diversity in codon (left panel) or amino acid (right panel) coordinates for each hotspot locus.
Interhost diversity was calculated across all global DENV-3 isolates for which full-genome sequences were available (n = 690).prM100, (2) methionine to leucine at prM101, and (3) histidine to
leucine at E315 (Figure 2B). prM100 and prM101 variants were
significantly more prevalent in plasma (59.3% and 62.9%,
respectively), compared with PBMC samples (2.9% and 1.4%,
respectively) (p < 0.0001, Fisher’s exact test), while the E315
variant was highly prevalent in both PBMC (77.6%) and plasma
(69.7%) samples (Figure 2C, average of read 1 and read 2404 Cell Host & Microbe 22, 400–410, September 13, 2017values). Hotspots detected were not PCR artifacts from the
amplicon and library preparation (data not shown). Even at lower
thresholds ofR0.5% variant abundance, the prM100 and prM101
variants were only detected in a small number of PBMC samples
(8.8%–13.2% of samples; Figure 2D). The E315 variants thus
appear to originate in PBMCs (in addition to other cell types),
whereas it is conceivable that the prM100 and prM101 variants
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arise in viral replication sites distinct from PBMCs, although we
have not ruled out the possibility that these variants arose in
PBMCs and are simply enriched in the extracellular environment.
The prM100,101 and E315 variants constitute 2.2% and 1.9%,
respectively, of an estimated 1.23 107 GE/mL of circulating viral
populations in plasma (extrapolated from Figure 1F;median yield
of 1.23 106 GE in 50 mL of RNA extracted from 100 mL of plasma)
from individuals with detectable levels (R1.0%) of these variants
(Figure S2C, median abundances). We also analyzed interhost
diversity in 690 full-length DENV-3 consensus genomes
(GenBank) and found that even though DENV-3 exhibited
codon-level diversity at prM100 and E315 (Figure 2E, left panel,
red bars), virus populations were invariant in the interhost amino
acid sequence at all three hotspots (Figure 2E, right panel, red
bars, and Table S2), suggestive of macro-evolutionary (i.e.,
consensus-level) constraints at these loci. In addition to major
hotspots, we detected several minor hotspots, defined as loci
with 1.0% or higher variant abundance in R10% of samples,
in both PBMC and plasma samples (Figure S2D, all minor hot-
spots marked with ^). Of these minor hotspots, only one (codon
1071 in polyprotein) appeared to be shared between PBMC and
plasma samples at a diversity threshold of 1.0% (Figure S2D). All
minor hotspots (loci marked with ^) exhibited interhost diversity
at the codon level (Figure S2E, left panel, red line, and Table S2),
but interhost amino acid diversity was only observed at five out of
nine minor hotspots (Figure S2E, right panel, red line, and Table
S2). Overall, our findings demonstrate that hotspots for intrahost
viral diversity can be detected in acute human dengue. Further-
more, the presence of hotspot variants at macroevolutionarily
conserved loci highlight the importance of host-specific selec-
tion pressures in DENV-3 intrahost evolution.
Convergent Evolution at Major Hotspot Loci
We next explored linkage patterns between polymorphisms in
the sequences of reconstructed haplotypes spanning the
prM100,101 and E315 major hotspot loci to identify whether (1) var-
iants at the prM100 and prM101 hotspot loci were present on the
same viral genome, and (2) viruses with variation at the
prM100,101 and E315 hotspots arose de novo in different samples
due to convergent selection pressures, or were present in multi-
ple hosts due to co-transmission with consensus viral genomes.
In samples with detectable levels of both prM variants at the
population level, we observed that all haplotypes with the
prM100 variant also included the prM101 variant (and vice versa),
demonstrating that the prM variants were linked, i.e., present on
the same variant viral genome (Figure 3A, red arrowheads).
Moreover, we identified haplotypes with variants at only one
prM hotspot (Figure S2F), which implied that DENV-3 was
evolving independently at each of the prM100 and prM101 hot-
spots. The prM100,101 variant thus appears to be the result of
sequential evolution at prM100 and prM101 on the same viralFigure 3. Sequence Diversity in Reconstructed Haplotypes Spanning t
Color-coded nucleotide diversity in regions flanking intrahost diversity hotspots i
with the hotspot variant in 8 PBMC/plasma samples for the prM/M hotspot and 3
lines). Consensus haplotypes and their observed frequencies across all Nicaragu
with the prM100,101 and E315 variants are denoted with asterisks (*), WT varian
underlined loci in B represent the AB-loop region containing the E hotspot. Red as
arrowheads, other variants present at >1% abundance.
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host diversity at three loci proximal to the prM100,101 and E315
hotspots (Figures 3A and 3B; black arrowheads). Four different
haplotypes with a wide range of frequencies were detected
among the consensus genomes in our samples, each with
unique combinations of nucleotide diversity at these loci (Figures
3A and 3B, and Table S3). Nucleotides at all three polymorphic
loci were 100% concordant between the dominant WT
consensus genome and the prM/M or E variant genome for all
samples (Figures 3A and 3B and Table S3; variant genomes
marked with *). This was true even for samples with low-fre-
quency consensus haplotypes (C-A-T and A-G-G haplotypes
for prM/M and E, respectively), and for samples in which mixed
infections with multiple WT haplotypes were detected (Figures
3A and 3B; genomes marked with #). The genetic concordance
between WT and variant haplotypes in our samples strongly
support the independent emergence and/or expansion of these
hotspot variants within each individual, although we cannot
completely exclude contributions from co-circulating variants
at the prM100,101 and E315 loci. Taken together, our observations
indicate that variants at the prM100,101 and E315 hotspot loci
arose by convergent evolution during acute dengue, in at least
four independent events, corresponding to the presence of the
variants in four distinct haplotypes.
Replication Phenotypes and Origins of Hotspot Variants
The four-plasmid reverse genetics approach (Messer et al.,
2012) was used to engineer chimeric infectious clones contain-
ing non-structural genes from a 1989 Sri Lankan DENV-3 isolate
(GenBank: JQ411814.1) and either (1) Nicaraguan consensus
sequence for the structural genes (WT), (2) WT Nicaraguan
consensus with the Gly100Ser and Met101Leu mutations in
the membrane portion of prM/M (prM100,101 mutant), or (3) WT
Nicaraguan consensus with the His315Leu mutation in the AB
loop in E (E315 mutant). We evaluated the replication phenotypes
of WT and mutant viruses in C6/36 mosquito cells by directly
competing eachmutant viruswithWT virus in co-infection exper-
iments (Quiner et al., 2014). Viral RNA mixtures from the input
and from cellular supernatants collected 3, 4, and 5 days post
infection (d.p.i.) were sequenced by the Sanger method to cap-
ture ratios of WT and mutant nucleotides at the prM100,101 and
E315 hotspots using the polySNP program. The replicative index,
calculated as the log2 value of relative levels of WT and mutant
viruses in the supernatant compared with relative levels in the
input, was negative for prM100,101 or E315 mutant viruses at
3–5 d.p.i., indicating that bothmutants were replication defective
in C6/36 cells compared with WT (Figure 4A). In addition, we
assessed the replication phenotypes of WT and mutant viruses
in a human monocytic U937 cell line that expresses DC-SIGN,
a co-receptor for DENV entry (Tassaneetrithep et al.,
2003) (U937-DC-SIGN). Single infections were performed inhe Intrahost Diversity Hotspots in prM/M and E
n (A) prM/M and (B) E; each row represents a unique reconstructed haplotype
9 PBMC/plasma samples for the E hotspot (samples delineated by thin white
an samples are shown on the left, separated by thick white lines. Haplotypes
t haplotypes distinct from the consensus haplotype are marked with #, and
terisk, furin cleavage site. Red arrowheads, prM and E hotspot variants. Black
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Figure 4. Phenotypic Differences between Wild-Type, prM100,101, and E315 Viruses
(A) C6/36 cells were infected with amixture containingWT virus and the prM100,101 (yellow) or E315 (red) mutant viruses. The replication index wasmeasured as the
log2 value of relative levels of mutant and WT genomes in the supernatant at 3–5 d.p.i., compared with the corresponding ratios in the input. A negative index
indicates that the replicative ability of mutant virus is lower than WT virus.
(B) U937-DC-SIGN cells were mock-infected (mock, blue) or infected withWT (aqua), prM100,101 (yellow), and E315 (red) viruses, fixed, and stained with anti-E (left
panel) and anti-NS3 (right panel) antibodies at various time points post infection. All data points for (A and B) represent the average of two independent
experiments, mean ± SD.U937-DC-SIGN cells with 625 GE/cell each of WT, prM100,101,
and E315 viruses. All three viruses were able to establish infection
in U937-DC-SIGN cells; however, the percent of infected cells
was considerably reduced in infections with prM100,101 and
E315 variants compared with WT virus at 1, 2, and 3 d.p.i., as
determined with both anti-E and anti-NS3 antibodies (Figure 4B,
left and right panels, respectively). No revertants were detected
at 3 d.p.i. with either variant (data not shown). The E315 variant
also exhibited a temperature-sensitive (32C versus 37C) pla-
quing phenotype on baby hamster kidney (BHK-21) cells with
better plaquing at 32C, whereas the prM100,101 variant plaqued
relatively well at 37C (Figure S4). Our results thus demonstrate
that the prM100,101 and E315mutant viruses establish infections in
C6/36 mosquito cells, U937-DC-SIGN human cells, and in
BHK-21mammalian cells with considerably reduced efficiencies
due to the deleterious effects of these mutations on viral replica-
tive ability.
The prM100,101 and E315 mutant viruses do not exhibit any
defects in entry and behave similar toWT virus, as demonstrated
by directly comparing entry capabilities of the three viruses using
U937-DC-SIGN cells at 37C (Figure S5), suggesting that the
replication defect for both prM100,101 and E315 mutant viruses is
downstream of virus entry. We do not anticipate that these
mutations have a direct impact on viral RNA replication, as
none of the DENV structural proteins, except RNA elements in
the Capsid gene (Byk and Gamarnik, 2016; Clyde et al., 2008;
de Borba et al., 2015; Friebe et al., 2011; Selisko et al., 2014),
have been implicated in a direct role in RNA replication. In studies
by Zheng et al. (2014), mutations at prM98 in DENV-1were shown
to result in impaired prM processing and decreased viral infec-
tivity. prM100 and prM101 are situated only 2–3 amino acids
away from prM98, and given the absence of entry and replication
defects, we hypothesize that the prM100,101 hotspot mutations
likely impair prM processing and DENV infectivity, by a mecha-
nism similar to prM98 (Zheng et al., 2014). Even though prM anti-
bodies have been identified by several groups (Beltramello et al.,
2010; Dejnirattisai et al., 2010), the immune pressures driving
evolution at the prM/M locus are poorly understood, and the
origin of the prM100,101 variant viruses remains elusive. Incontrast, significantly more is known about the functionalities
and antigenicity of loci in the E protein, and specifically the E315
locus. Previous studies have shown that E315 plays a pH-sensing
role in mediating viral fusion with the endosome at the post-entry
stage (Nelson et al., 2009), suggesting that viruses with the E315
hotspot mutation are likely impaired at the stage of viral mem-
brane fusion with the endosomal membrane. Interestingly, the
process of viral membrane fusion appears to be a significant
target of anti-DENV antibodies during infection in humans, with
fusion loop antibodies making up a significant proportion of the
population of broadly reactive antibodies that are elicited during
infection with DENV (Goncalvez et al., 2004; Lai et al., 2013).
Given the convergent nature of the immune response and the
prevalence of the E315 variant, it is conceivable that the E315
variant arose as an immune-escape variant to fusion loop anti-
bodies. Indeed, Goncalvez et al. (2004) demonstrated that after
11 cycles of passage in the presence of anti-fusion loop mAb
1A5, an escape mutation was isolated at E317 in DENV-2, further
supporting our claim that immune pressures exerted by fusion
loop antibodies played a key role in convergent selection for var-
iants at the analogous E315 hotspot locus in DENV-3. Taken
together, we conclude that the E315 hotspot variant, despite
possibly possessing an immune-escape advantage, is con-
strained to the intrahost evolutionary system because of the
severe defects associatedwith viral membrane fusion post entry.
Concluding Remarks
We have thus demonstrated that intrahost DENV-3 populations
can rapidly and convergently evolve in acute human infections,
with virus microevolution possibly shaped by viral replication
compartments distinct from PBMCs, driven in part by immune
selection pressures and constrained by replication defects at
the macro-evolutionary scale. In particular, we identified a highly
prevalent DENV variant (E315) that likely arose as an immune-
escape variant in response to pressures exerted by fusion loop
antibodies, yet was constrained by severe replicative defects
likely incurred due to a deficiency in viral membrane fusion
with the host endosome post entry. The identification of such
convergent immune pressures that appear to result in theCell Host & Microbe 22, 400–410, September 13, 2017 407
selection of prevalent immune-escape variants, especially ones
that are constrained by replication defects or fitness costs, could
be harnessed for intelligent selection of new candidates and
targets for vaccine/drug design. Such snapshots of intrahost
DENV diversity help to identify mechanisms driving virus micro-
evolution in human dengue and provide new perspectives in as-
sessing infection outcome, disease pathogenesis, and vaccine/
therapeutic efficacy in individuals.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethics Statement
All studies were approved by the Institutional Review Boards (IRBs) of the University of California, Berkeley, and of the Nicaraguan
Ministry of Health. Written consent was obtained from the parents/legal guardians of all pediatric subjects. Assent was also obtained
from subjects six years of age or older.
Study Population
PBMC and plasma samples were obtained from subjects in an ongoing prospective hospital-based study of pediatric dengue in
Nicaragua established in 1998 (Hammond et al., 2005), which enrolls patients who present with suspected dengue to the National
Pediatric Reference Hospital in Managua, Nicaragua. Plasma and PBMCs are collected from patients for three sequential days
during the acute phase of illness, at convalescence (days 14-28) and longitudinally for 18months. Criteria for identifying dengue-pos-
itive cases and for classifying by immune status are as described (Gutierrez et al., 2013; Narvaez et al., 2011). Dengue cases are
classified as DF, DHF, or DSS according to the 1997 WHO Dengue Guidelines (Narvaez et al., 2011; WHO, 1997). Thirty-one plasma
and 68 peripheral bloodmononuclear cell (PBMC) samples from 77 individuals (including 22 with paired plasma and PBMC samples)
were analyzed in this study. The gender identity as well as the age of the patients is listed in Table S1. Extensive epidemiological and
clinical data are available for these samples. The sample size for this studywas determined by availability of pediatric patient samples
for primary and secondary dengue cases caused by DENV-3 within a single endemic year (2009-2010). Subgroups within the 77 pa-
tients in the study were selected based on sample type (plasma versus PBMCs), clinical classification (for example, primary versus
secondary dengue, Dengue Fever versus Dengue Hemorrhagic Fever and Dengue Shock Syndrome), or gene origin of variation
(based on DENV-3 gene annotation).
Cell Culture
Baby hamster kidney cells (BHK-21 clone 15) weremaintained in aMEM (Gibco) supplementedwith 5%heat-inactivated Fetal Bovine
Serum (FBS; Gibco), 10 mM HEPES (Gibco), and 100 U/ml penicillin and 100 mg/ml streptomycin (Pen/Strep; Gibco) at 37C in 5%
CO2. C6/36 cells (gift of Dr. Ralph Baric) weremaintained inMEMwith HEPES supplementedwith 10%heat-inactivated FBS, 1X non-
essential amino acids (NEAA; Gibco), 2 mM L-glutamine (Gibco) and Pen/Strep at 32C in 5% CO2. U937 cells expressing DC-SIGN
(U937-DC-SIGN, gift of Dr. Aravinda de Silva) were maintained in RPMI 1640 medium (Gibco) supplemented with 5% FBS, 1% Pen/
Strep and 1% HEPES at 37C in 5% CO2.
METHOD DETAILS
RNA Extraction and DENV-3 Genome Amplification
A hybrid TRIzol/RNeasy protocol was developed for viral RNA recovery from PBMCs. Briefly, PBMCs were lysed in TRIzol (Life
Technologies), and aqueous phase RNA was extracted after addition of chloroform. Next, 3.5 volumes of Buffer RLT (RNeasy
Mini kit; Qiagen) and 2.5 volumes of 100% ethanol were added to the RNA solution, and the mixture was applied to an RNeasy
column. All washes and RNA elutions were performed as described (RNeasy kit protocol). Viral RNA from plasma samples was
extracted using the QIAamp Viral RNA Mini Kit (Qiagen) as described in the manufacturer’s protocol. RNA was eluted in 50 ml of
RNase-free water containing linear polyacrylamide (1 ml; Life Technologies), carrier RNA (0.1 ml; Qiagen), and SUPERase-In (1 ml;
Life Technologies). Twelve RT/PCR amplifications were set up for each sample, with various combinations of forward and reverse
primers (Table S4) and reagents from the SuperScript III One-Step RT-PCR System (Invitrogen). For each reaction, we used 5 ule2 Cell Host & Microbe 22, 400–410.e1–e5, September 13, 2017
of denatured RNA, 17.5 ul of a 2X reaction mix, 0.25 ul each of forward and reverse primers (100 uM), 0.7ul of the enzyme mix, and
11.3 ul of RNase-free water. DENV-3 RNAwas reverse-transcribed (50C for 60 minutes) and cDNAwas amplified as follows: 1 cycle
of denaturation (94C for 2 minutes), 35 cycles of denaturation (94C for 15 seconds), annealing (55C for 30 seconds), and extension
(68C for 3minutes), and a final extension step (68C for 10minutes)}. The conditions were identical for all amplicons except amplicon
4, for which the extension time was shortened to 1 minute. DENV-3 amplicons were purified on a 1% agarose gel, and DNA was
recovered using the QIAquick Gel Extraction Kit (Qiagen). For each sample, PCR amplicons were pooled in equimolar ratios, and
indexed libraries were prepared for high-throughput sequencing using the Nextera XTDNASample Preparation Kit (Illumina). Nextera
XT libraries were pooled and sequenced for 150 cycles in two lanes on Illumina’s HiSeq 2000 platform to generate paired-end
datasets.
Consensus Genome Imputation and Variant Analysis
Reads were segregated based on their forward (read 1) and reverse (read 2) indices. The paired-end datasets for reads 1 and 2 were
analyzed separately for all samples.
Filtering for Read Quality
The Fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) was used to (a) trim reads with low quality (<Q30) at the 3’ end, (b) remove
reads less than 50 nucleotides in length, and (c) only retain reads of high quality sequence (RQ30) atR90% of read length.
Read Alignments and Variant Identification
Wegenerated aDENV-3 consensus genome based on all sequencedNicaraguanDENV-3 isolates from the 2009-2010 epidemic year
(n = 108; NCBI Virus Variation Database). Read 1 and read 2 datasets for each sample were aligned to the Nicaraguan DENV-3
consensus genome using Bowtie2 (Langmead and Salzberg, 2012). SAMtools (Li et al., 2009) was used to create a pileup file
from theBowtie2 output, and pileup fileswere filtered based on aminimum read quality score of 30 andminimumcoverage of 5 reads.
Consensus genomes were created for each dataset using in-house scripts, and gaps were filled with Nicaraguan DENV-3 consensus
sequences. All datasets were re-aligned to their corresponding consensus genomes using Bowtie2, and pileup files generated by
SAMtools were filtered based on quality scores (R30). Fastq files for all the sequences generated in this study have been deposited
into NCBI’s Sequence Read Archive, and can be accessed using BioProject ID PRJNA394021. In-house scripts were used to calcu-
late percent variant abundance in nucleotide, codon and amino acid coordinates at all loci with a minimum coverage of 5 reads.
Threshold for Variant Abundance
Replicate amplicon libraries were analyzed in a pairwise manner to set abundance thresholds for high-confidence variant detection.
In replicate amplicon libraries from four PBMCsamples, all variants that were detected at an abundance ofR0.5% in replicate Awere
also detected in replicate B (Figure S1B, left panels) and vice versa (data not shown). However, the threshold for variant detection in
both replicates was considerably higher for replicate libraries from the three serum samples (R1.0%; Figure S1B, right panels).
Additionally, frequency distribution of loci by percent variant abundance in replicate B, for various thresholds of percent variant
abundances in replicate A, revealed that concordance of 50% or higher between replicates was achieved at loci withR1.0% variant
abundance in both PBMC and serum samples (Figure S1C, left and right panels, respectively). For identifying variants, we imple-
mented the following thresholds: (a) loci should have a minimum coverage of 1000 reads, (b) variant abundance must be R1%,
and (c) variant cannot be in a primer-binding region.
Reconstructing Haplotypes
The software package ShoRAH (Zagordi et al., 2011) was used to reconstruct 150 nucleotide-haplotypes spanning the prM100,101
and E315 hotspot loci. Only haplotypes with a reconstruction quality score ofR0.9 were considered for diversity analysis.
Generation of WT, prM100,101 and E315 DENV-3 Viruses
A four-plasmid infectious clone system (plasmids A-D; gift of Dr. Ralph Baric (Messer et al., 2012)) based on a Sri Lankan DENV-3
template was used to derive Nicaraguan WT DENV-3 and DENV-3 with mutations at the prM100,101 or E315 hotspot loci. We intro-
duced four amino acid changes in the C, prM and E sequences in plasmid A (P27S, I286V, V361T and A609V in the DENV-3
polyprotein) to generate infectious clones that were identical in structural protein sequence to the Nicaraguan DENV-3 consensus
genome (‘‘WT’’). The prM100,101 mutations were inserted by site-directed mutagenesis in plasmid A using the QuikChange
site-directed mutagenesis kit (Stratagene). The E315 mutation was synthesized in the context of a plasmid A fragment spanning nu-
cleotides 1-2034 of the DENV-3 genome (Bio Basic, Inc.). Infectious clones for WT, prM100,101 and E315 viruses were derived as
described (Messer et al., 2012), with somemodifications. All plasmids were individually propagated in E. coli TOP10 competent cells
(Invitrogen) and grown on LB plates with selective antibiotics (plasmid A encoding for WT, prM100,101 and E315 was selected with
ampicillin, plasmids B and C with kanamycin, and plasmid D with chloramphenicol) at 30C for 24 hours. Sequences of colony-
purified plasmids were confirmed by Sanger sequencing, and restriction digests were set up as follows: plasmid A with SpeI,
AhdI and BsmBI yielding a 2.0-kb fragment; plasmid B with BglI and BsmBI yielding a 1.1-kb fragment; plasmid C with BglI yielding
a 3.9-kb fragment; and plasmid D with BglI and BsmbI yielding a 3.0-kb fragment. Fragments were gel-purified using a MinElute Gel
Extraction Kit (Qiagen), mixed in equimolar ratios, and ligated with T4 ligase (NEB) for 2 hours at 16C. Full-length transcripts of
DENV-3 cDNA constructs were generated in vitro as described using the mMessage mMachine T7 Kit (Ambion) with the following
modifications: (a) 20 ml reaction mixtures were supplemented with 2 ml of a 30 mM GTP stock, resulting in a 1.3:1 ratio of cap analog
to GTP, and (b) the reaction was incubated at 37C for 3 hours. For electroporation, DENV-3 transcripts were added to 400 ml of BHK
cell suspension (1 x 107 cells/ml in RNase-free PBS) in an electroporation cuvette, and pulsed once with 270 V (975 mF) in a Bio-RadCell Host & Microbe 22, 400–410.e1–e5, September 13, 2017 e3
Gene Pulser II electroporator. The transfected BHK cells were grown in a 75 cm2 flask and incubated at 37C for 5 days. For virus
amplification, 2 ml of viral supernatant from BHK cells was used to infect C6/36 cells in a 75 cm2 flask, and 18 ml of C6/36 media
(1X MEM + 2% FBS + 1% Pen/Strep + 1% NEAA + 1% L-Glutamine) was added to the cells. Supernatants were harvested five
days post-infection, supplemented to 1X SPG (sucrose-phosphate-glutamate stabilizer, prepared in-house), clarified by centrifuga-
tion, and frozen at 80C or passaged serially in C6/36 cells.
Virus Titration
For plaque assays, ten-fold serial dilutions of virus culture supernatant (undiluted, and dilutions of 101 to 105) were added in dupli-
cate to cultured BHK-21 cells in 24-well plates and incubated for 1 h at 37C. After discarding the inoculum, the cells were overlaid
with 1 ml of 0.8% carboxymethyl cellulose in MEM supplemented with 2% FBS and Pen/Strep. Plates were incubated for 4 days at
37C in 5% CO2. Overlays were removed, cells were fixed with formalin and stained with 2.5% crystal violet in 30% ethanol, and
plaque-forming units per ml (PFU/ml) were counted. For assaying temperature sensitivity, infections and post-infection incubations
were performed at 32C in 5%CO2, and plaques were counted 7 days p.i.. For quantitative RT-PCR (qRT-PCR), 18 ml-reactions were
set up with 2 ml RNA, DENV-3 specific primers (Johnson et al., 2005), 0.1 mMDENV-3 probe (Johnson et al., 2005), and reagents from
the Verso 1-Step qRT-PCR kit (Thermo Scientific). Reaction conditions were as follows: 1 cycle of reverse transcription (30minutes at
50C), 1 cycle of Thermo-Start activation (12.5 minutes at 95C), and 40 cycles of denaturation (15 seconds at 95C) and annealing/
extension (1 minute at 60C). A standard curve was used to calculate DENV-3 genome equivalents per ml (GE/ml) for each test
sample.
Relative Quantitation of Viruses by Sequencing
Viral RNA was amplified using reagents from the SuperScript III One-Step RT-PCR System, with primers (5’- GACTCGGAA
GCTTGCTTAAC-3’ and 5’-TATTGACAGGCTCCTCCTTCTTAG-3’) designed to capture the prM100,101 and E315 hotspot loci. Ampli-
cons were gel-purified and sequenced by the Sanger method using primers 5’-TCAATATGCTGAAACGCGTG-3’ and 5’-CGGACA
GGTTTGGATTTCAATG-3’ for capturing chromatogram peak heights at the prM100,101 and E315 loci, respectively. Relative levels
of WT and mutant viruses were calculated from quantitation of chromatogram peak heights at the hotspot loci corresponding to
WT and mutant nucleotides using the PolySNP program (Hall and Little, 2007).
Replication in C6/36 Cells
For each infection, we used six-well plates with 2 X 105 C6/36 cells per well, and a virus mix containing 1000 GE/cell of WT and 1000
GE/cell of prM100,101 or E315 viruses (as determined by qRT-PCR) diluted in Hank’s Balanced Salt Solution (HBSS; Gibco). One
hundred ml of the virus mix was stored for assessing input ratios. C6/36 cells were infected with each virus mix for 2 h at 32C in
5% CO2, washed with PBS, and incubated in MEM containing 2% FBS, 1% Pen/Strep, 1% NEAA and 1% L-Glutamine. Superna-
tants were collected from independent wells at 3, 4 and 5 d.p.i.. Viral RNA was extracted from supernatants and the input virus mix
using the QIAamp Viral RNA kit (Qiagen). All experiments were performed in duplicate. Relative levels of WT andmutant viruses were
estimated using Sanger sequencing and the polySNP program (Hall and Little, 2007).
Replication in U937-DC-SIGN Cells
Infections were set up in 96-well plates with 5 x 104 U937-DC-SIGN cells per well. Infections were performed with 625 GE/cell of WT,
prM100,101 or E315 viruses, diluted in HBSS. Cells were infected with each virus mix for 2 h at 37
C in 5%CO2, washed and incubated
in medium containing RPMI 1640, 2% FBS, 1%Pen/Strep and 1%HEPES for 24, 48 or 72 h at 37C in 5%CO2. Cells were stained at
room temperature with a 1:500 dilution of Zombie Aqua stain (BioLegend), fixed, permeabilized, and stained with a 1:250 dilution of
an anti-E (5D4) (Henchal et al., 1982) monoclonal antibody conjugated to Texas Red and a 1:500 dilution of an anti-NS3 (E1D8)
(Balsitis et al., 2009) monoclonal antibody conjugated to APC. All experiments were performed in duplicate. The percent of infected
cells was measured via flow cytometry on an LSR Fortessa cell analyzer (BD Biosciences), and the data were analyzed using FlowJo
8.8.7 software (TreeStar).
RT-PCR from Serum
Reverse primers specific for WT or E315 mutant virus were designed as follows: primer WT (DV3Ewt_r: CGACCTTAATGAG
TATTGTCCCAT); primer E315 (DV3E*_r: CGACCTTAATGAGTATTGTCCCAa). In combination with the forward primer
PP49_DENV3_32_F (GACTCGGAAGCTTGCTTAAC), both primer sets generated an RT-PCR amplicon of 1,865bp. RT-PCR was
carried out using SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity (Invitrogen). The RT-PCR products
were visualized using an agarose gel (1%).
Entry Assays
The entry assay was performed as previously described (Diamond and Harris, 2001) with slight modifications. Specifically, 10ml of
U937-DC-SIGN cells (1x107 cells/ml, total of 1x105 cells) was aliquoted into microcentrifuge tubes in triplicate, mixed with WT virus
(multiplicity of infection of 0.5), E315 variant virus or prM100,101 variant virus diluted in 240ml of U937-DC-SIGN culture medium, and
incubated at 37C for 2 hours with occasional agitation to avoid pelleting. All samples were then iced and washed three times withe4 Cell Host & Microbe 22, 400–410.e1–e5, September 13, 2017
500ml of U937-DC-SIGN culturemedium at 4C, andwashed twice with 500ml PBS at 4C. Then 350ml of lysis buffer was added to cell
pellets, and RNA extraction was performed using RNeasy Mini Kit (QIAGEN). qRT-PCR was performed as described above.
QUANTIFICATION AND STATISTICAL ANALYSIS
Different statistical analyses were performed and are specified in the corresponding results in the main text or in figure legends when
describing the analysis, such as Fisher’s exact test (Figure 2C, main text), Wilcoxon test for unpaired samples (Figure 1B, figure
legend), Wilcoxon signed-rank test (Figures 1A, 1D, and 1E, figure legend), Wilcoxon signed-rank test for paired samples (Figure 1F,
figure legend). Significance was generally defined as *P%0.01, **P%0.001, while P < 0.0001 was also indicated where applicable.
The number of samples (n) used for all comparisons is indicated in the figure legends as well as in the main text. Briefly, samples
from 53 individuals with 1 and 46 individuals with 2 dengue were used for comparisons presented in Figures 1A–1C. Samples
from 22 paired PBMC and plasma samples were used in Figures 1D and 1E. Samples from 12 paired PBMC and plasma samples
were used in Figure 1F. Samples from 68 PBMC and 31 plasma samples were used in Figures 2A–2D. In Figure 2E, 690 full-length
DENV-3 genomes were analyzed. Data from 8 PBMC/plasma samples (prM/M hotspot) and 39 PBMC/plasma samples (E hotspot)
are shown in Figure 3. Data from 2 independent experiments were used in Figure 4.
DATA AND SOFTWARE AVAILABILITY
Fastq files for all the sequences generated in this study have been deposited into NCBI’s Sequence Read Archive, and can be
accessed using BioProject ID PRJNA394021.Cell Host & Microbe 22, 400–410.e1–e5, September 13, 2017 e5
